Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin (2022 - 2025)

Historic EBT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 349.08%.

  • bioAffinity Technologies' EBT Margin fell 2640600.0% to 349.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 216.89%, marking a year-over-year decrease of 1268800.0%. This contributed to the annual value of 96.43% for FY2024, which is 2161400.0% up from last year.
  • As of Q3 2025, bioAffinity Technologies' EBT Margin stood at 349.08%, which was down 2640600.0% from 317.59% recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBT Margin ranged from a high of 81.37% in Q1 2024 and a low of 427752.87% during Q3 2022
  • Over the past 4 years, bioAffinity Technologies' median EBT Margin value was 333.34% (recorded in 2025), while the average stood at 48706.01%.
  • Data for bioAffinity Technologies' EBT Margin shows a peak YoY increase of 2000000000bps (in 2023) and a maximum YoY decrease of -20510100bps (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows bioAffinity Technologies' EBT Margin stood at 71380.39% in 2022, then soared by 100bps to 107.12% in 2023, then decreased by -25bps to 134.4% in 2024, then plummeted by -160bps to 349.08% in 2025.
  • Its last three reported values are 349.08% in Q3 2025, 317.59% for Q2 2025, and 143.06% during Q1 2025.